Lynch Biologics Acquired by Geistlich Pharma

Oct 28, 2022 | Featured

pH Partners Serves as Exclusive Financial Advisor to Lynch Biologics, LLC

Franklin, TN, October 27, 2022 — pH Partners, LLC, a healthcare investment bank, is pleased to announce that its client, Lynch Biologics, LLC, founded by Dr. Sam Lynch, DMD, DMSC, has been acquired by Geistlich Pharma North America, a global leader in regenerative dentistry.

Lynch Biologics (LBIO) is an innovative biologics and tissue engineering company at the cutting edge of dental and craniofacial regeneration. Lynch is the developer and sole provider of GEM 21S®, the first recombinant growth factor product for use in oral regenerative surgery. GEM 21S® is the only dental therapy containing rhPDGF-BB, one of the primary growth factors found in the human body and well known for its stimulatory role in wound healing.

Lynch’s commitment to medical regeneration and proven product GEM 21S® hallmark the significance of their acquisition to Geistlich. Dr. Sam Lynch, CEO of Lynch Biologics, stated, “I believe this is an exciting opportunity as we bring together the companies with the most widely used biologic and the world market leader in dental biomaterials, which is an ideal combination to serve our customers in the oral regenerative space” (Inc., 2022).

Together, these companies will share a mission to advance new regenerative technologies in dentistry to improve healing and bone regeneration, ultimately leading to better outcomes and satisfaction among dental patients.

pH Partners, LLC, served as the Exclusive Financial Advisor to Lynch Biologics.

To read more, visit the press release here.

 

About pH Partners

pH Partners, LLC is a boutique investment banking firm delivering capital formation, partnership, merger, and acquisition solutions to companies at the convergence of Healthcare, Technology, and the Consumer. The pH Partners team comprises senior-level executives with extensive backgrounds in investment banking, life sciences, medicine, and operations. Our team has collectively closed over $20B in strategic advisory transactions and raised more than $5B in capital for our clients. pH Partners is headquartered in Austin, Texas, with offices in Houston, Minneapolis, Portland, and New York. To learn more, visit phpartners.com.

pH Partners’ transaction lead:

Benjamin Perkins 

pH Partners, LLC

Managing Partner

Ben@phpartners.com

 

 

Source

Inc., G. P. (2022, October 27). Geistlich Pharma North America, Inc. acquires Lynch Biologics, LLC, a biologics and tissue engineering company. Retrieved from Cision PR Newswire: https://www.prnewswire.com/news-releases/geistlich-pharma-north-america-inc-acquires-lynch-biologics-llc-a-biologics-and-tissue-engineering-company-301661372.html